Background: Chronic hypercapnic respiratory failure (HRF) in obesity hypoventilation syndrome (OHS) is commonly treated using non-invasive ventilation (NIV). We hypothesised that treatment of OHS would improve neural respiratory drive index (NRDI) and cardiac function.Methods: Fourteen patients (8 females) with OHS, who were admitted for initiation of domiciliary NIV, were prospectively studied. Patients had (mean ± SD): age (53±10 years), body mass index (BMI) (50.1± 10.8 kg/m 2 ), and pCO 2 (7.3±0.9 kPa). NRDI was assessed by surface electromyogram of the parasternal intercostals. Cardiac function was assessed by transthoracic echocardiography (TTE). All measurements were performed at baseline, 6 weeks, and 3 months.Results: NRDI improved on day one following NIV set-up comparing to baseline (484.2±214.8 vs.316.5±106.5 AU) and this improvement was maintained at 6 weeks (369.1±173.2 AU) and at 3 months Conclusions: NIV improves NRDI in patients with OHS, while the cardiac function over a three-month period remains unchanged.
BackgroundChronic hypercapnic respiratory failure in obesity hypoventilation syndrome (OHS) is commonly treated with non-invasive ventilation (NIV). We hypothesised that treatment of OHS would improve neural respiratory drive (NRD) and improve cardiac function.Patients and methodsA prospective, observational single-centre study was conducted. OHS patients were assessed recording NRD, as measured by the electromyogram of the parasternal intercostals (EMGpara) before, during and after NIV set-up and cardiac function with trans-thoracic echocardiography (TTE) before and after NIV set-up. Follow up appointments were planned at 6-weeks (6W-FU) and 3 Months (3M-FU). The tricuspid annular plane systolic excursion (TAPSE) score was used to assess the right ventricular (RV) function and EMGpara%max and neural respiratory drive index (NRDI) were recorded to assess NRD. The Wilcoxon test was used to compare baseline with follow-up results.Results10 patients (age 55.9 (7.6) years, females 50%, weight 126.6 (29.1) kg, BMI 48.1 (7.5) kg/m2) were studied. 3 patients were non-compliant with NIV. NRDI and EMGpara%maxsignificantly improved following NIV set-up, and this effect was maintained at 3M-FU (EMGpara%max 24.4 (12.9)%, 16.9 (5.4)% and 18.6 (6.5)%, p = 0.028 and p = 0.035; NRDI 480.4 (256.0)/min, 314.7 (125.6)/min and 379.5 (138.0)/min, p = 0.22 and p = 0.012; Figure 1).There were no significant differences in cardiac function between baseline and 3M-FU (TAPSE: 2.6 (0.6) mm vs. 2.4 (0.4) mm, p = 1.00) or systolic pulmonary artery pressures (sPAP 36.7 (15.2) mmHg vs 35.8 (16.2) mmHg, p: 0.50). The TAPSE score in compliant patients seemed to improve (n = 3; 2.3 (0.6) mm vs. 2.7 (0.3) mm) while non compliant patients experienced a deterioration (n = 3; 2.7 (0.5) mm vs. 2.2 (0.4) mm).ConclusionsNIV improves NRD and respiratory parameters in patients with OHS. However, cardiac function does not improve over a three-month period despite the significant improvements in ventilation. These results are influenced by treatment adherence.Abstract S56 Figure 1EMG para%max improves following setup of NIV And at 3 month in OHS: (*): p < 0.05
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.